Health Care & Life Sciences » Pharmaceuticals | Reata Pharmaceuticals Inc.

Reata Pharmaceuticals Inc. Cl A | Income Statement

Fiscal year is January-December. All values USD Thousands.
2014
2015
2016
2017
2018
Sales/Revenue
51,954.00
50,319.00
49,856.00
48,058.00
53,589
SG&A Expense
45,817.00
48,834.00
56,056.00
94,533.00
130,036
EBIT
3,625.00
334.00
6,882.00
46,912.00
76,878
Non Operating Income/Expense
-
-
-
3.00
-
Interest Expense
-
-
-
1,454.00
6,176
Pretax Income
3,668.00
302.00
6,668.00
47,668.00
80,520
Income Tax
2,979.00
1,148.00
441.00
3.00
26
Consolidated Net Income
689.00
1,450.00
6,227.00
47,671.00
80,546
Net Income
689.00
1,450.00
6,227.00
47,671.00
80,546
Net Income After Extraordinaries
689.00
1,450.00
6,227.00
47,671.00
80,546
Net Income Available to Common
689.00
1,450.00
6,227.00
47,671.00
80,546
EPS (Basic)
0.03
0.06
0.31
1.99
2.91
Basic Shares Outstanding
22,323.10
22,323.10
19,816.60
23,933.30
27,701.80
EPS (Diluted)
0.03
0.06
0.31
1.99
2.91
Diluted Shares Outstanding
22,323.10
22,323.10
19,816.60
23,933.30
27,701.80
EBITDA
6,137.00
1,485.00
6,200.00
46,475.00
76,447
Non-Operating Interest Income
43.00
32.00
214.00
701.00
3,541

About Reata Pharmaceuticals

View Profile
Address
2801 Gateway Drive
Irving Texas 75063
United States
Employees -
Website http://www.reatapharma.com
Updated 07/08/2019
Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its lead product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.